



(19) REPUBLIKA HRVATSKA
DRŽAVNI ZAVOD ZA
INTELEKTUALNO VLASNIŠTVO

(10) Identifikator
dokumenta:



HR P20192337 T1

HR P20192337 T1

(12) **PRIJEVOD PATENTNIH ZAHTEVA
EUROPSKOG PATENTA**

(51) MKP:

C07K 7/56 (2006.01)
C07K 7/08 (2006.01)
A61K 38/12 (2006.01)
G01N 33/68 (2006.01)

(46) Datum objave prijevoda patentnih zahtjeva: 20.03.2020.

(21) Broj predmeta: P20192337T

(22) Datum podnošenja zahtjeva u HR: 30.12.2019.

(86) Broj međunarodne prijave: PCT/US2014026138
Datum podnošenja međunarodne prijave: 13.03.2014.

(96) Broj europske prijave patenta: EP 14727649.7
Datum podnošenja europske prijave patenta: 13.03.2014.

(87) Broj međunarodne objave: WO 2014151634
Datum međunarodne objave: 25.09.2014.

(97) Broj objave europske prijave patenta: EP 2970390 A1
Datum objave europske prijave patenta: 20.01.2016.

(97) Broj objave europskog patenta: EP 2970390 B1
Datum objave europskog patenta: 06.11.2019.

(31) Broj prve prijave: 201361794589 P (32) Datum podnošenja prve prijave: 15.03.2013. (33) Država ili organizacija podnošenja prve prijave: US
201361918184 P 19.12.2013. US
201414201977 10.03.2014. US

(73) Nositelj patenta:

**Bristol-Myers Squibb Company, Route 206 and Province Line Road,
Princeton, NJ 08543, US**

(72) Izumitelji:

**Michael Matthew Miller, c/o Bristol-Myers Squibb Company, Route 206
and Province Line Road, Princeton, NJ 08543, US**

**Claudio Mapelli, c/o Bristol-Myers Squibb Company, Route 206 and
Province Line Road, Princeton, NJ 08543, US**

**Martin Patrick Allen, c/o Bristol-Myers Squibb Company, Route 206 and
Province Line Road, Princeton, NJ 08543, US**

**Michael S. Bowsher, c/o Bristol-Myers Squibb Company 5 Research
Parkway, Wallingford, CT 06492, US**

**Kenneth M. Boy, c/o Bristol-Myers Squibb Company, 5 Research
Parkway, Wallingford, CT 06492, US**

**Eric P. Gillis, c/o Bristol-Myers Squibb Company 5 Research Parkway,
Wallingford, CT 06492, US**

**David R. Langley, c/o Bristol-Myers Squibb Company, 5 Research
Parkway, Wallingford, CT 06492, US**

**Eric Mull, c/o Bristol-Myers Squibb Company, 5 Research Parkway,
Wallingford, CT 06492, US**

**Maude A. Poirier, c/o Bristol-Myers Squibb Company, Route 206 and
Province Line Road, Princeton, NJ 08543, US**

Nishith Sanghvi, 3 Kershaw Court, Bridgewater, NJ 08807, US

**Li-Qiang Sun, c/o Bristol-Myers Squibb Company, 5 Research Parkway,
Wallingford, CT 06492, US**

**Daniel J. Tenney, c/o Bristol-Myers Squibb Company, 5 Research
Parkway, 2 Wallingford, CT 0649, US**

HR P20192337 T1



(19) REPUBLIKA HRVATSKA
DRŽAVNI ZAVOD ZA
INTELEKTUALNO VLASNIŠTVO

(10) Identifikator
dokumenta:



HR P20192337 T1

HR P20192337 T1

(12) **PRIJEVOD PATENTNIH ZAHTJEVA
EUROPSKOG PATENTA**

Kap-Sun Yeung, c/o Bristol-Myers Squibb Company, 5 Research
Parkway, Wallingford, CT 06492, US
Juliang Zhu, 22 Windsor Road East, North Haven, CT 06473, US
Patrick C. Reid, 1-17-10 Eifukucho, Suginami-Ku, 168-0064 Tokyo, JP
Paul Michael Scola, c/o Bristol-Myers Squibb Company, 5 Research
Parkway, Wallingford, CT 06492, US
Odvjetnica Gorana Grubišić, dipl.iur., 10000 Zagreb, HR


(74) Zastupnik:





(54) Naziv izuma: **MAKROCIKLIČNI INHIBITORI PD-1/PD-L1 I CD80(B7-1)/PD-L1 PROTEIN/PROTEIN
INTERAKCIJA**





HR P20192337 T1





PATENTNI ZAHTJEVI





1. Spoj odabran od:




















;







;







;






;






























;







;








;







;
































;




;




;






;









;









;

















;








;









;

























;




;




;




;




;




;




;




;







;




;




;









;






;




;














;








;









;







































ili njegova farmaceutski prihvatljiva sol.

2. Spoj ili farmaceutski prihvatljiva sol istih u skladu sa patentnim zahtjevom 1 za primjenu u poboljšavanju, stimuliranju, i/ili povećavanju imunog odgovora kod subjekta kod kojega postoji potreba za time.
- 5 3. Spoj ili farmaceutski prihvatljiva sol istih za primjenu u skladu sa patentnim zahtjevom 2 sa dodatnim agensom prije, nakon, ili simultano sa makrocikličkim peptidom ili peptidima opisanim ovdje.
4. Spoj ili farmaceutski prihvatljiva sol istih za primjenu u skladu sa patentnim zahtjevom 3 gdje dodatni agens je antimikrobni agens, antivirusni agens, citotoksični agens, i/ili modifikator imunog odgovora.
5. Spoj ili farmaceutski prihvatljiva sol istih u skladu sa bilo kojim od patentnog zahtjeva 1 za primjenu u inhibiranju rasta, proliferacije, ili metastaze kancerskih stanica kod subjekta kod kojega postoji potreba za time.
- 10 6. Spoj ili farmaceutski prihvatljiva sol istih za primjenu u skladu sa patentnim zahtjevom 5 gdje kancer je odabran od melanoma, karcinoma bubrežnih stanica, skvamoznog nesitnostaničnog kancera pluća (squamous non-small cell lung cancer - NSCLC), ne-skvamoznog NSCLC, kolorektalnog kancera, kancera prostate rezistentnog na kastraciju, kancera ovarija, kancera želuca, hepatocelularnog karcinoma, pankreasnog karcinoma, karcinoma skvamoznih stanica glave i vrata, karcinoma jednjaka, gastrointestinalnog trakta i dojke, i hematološkog maligniteta.
- 15 7. Spoj ili farmaceutski prihvatljiva sol istih u skladu sa patentnim zahtjevom 1 za primjenu u liječenju infektivne bolesti kod subjekta kod kojega postoji potreba za time.
8. Spoj ili farmaceutski prihvatljiva sol istih za primjenu u skladu sa patentnim zahtjevom 7 gdje infektivna bolest je uzrokovana virusom.
- 20 9. Spoj ili farmaceutski prihvatljiva sol istih za primjenu u skladu sa patentnim zahtjevom 8 gdje virus je odabran od HIV-a, Hepatitisa A, Hepatitisa B, Hepatitisa C, herpes virusa, i influence.
10. Spoj ili farmaceutski prihvatljiva sol istih u skladu sa patentnim zahtjevom 1 za primjenu u liječenju septičkog šoka kod subjekta kod kojega postoji potreba za time.
- 25 11. Spoj ili farmaceutski prihvatljiva sol istih u skladu sa patentnim zahtjevom 1 za primjenu u blokiranju interakcije PD-L1 sa PD-1 i/ili CD80 kod subjekta.